Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 18, 2006 Brian Lawler	Seeing the Forest Through the Trees Underappreciated Forest Labs continues its trend of strong growth. Trading at roughly 20 times its forward earnings guidance even with a much higher level of R&D spending, here is a company that investors shouldn't lose sight of amidst the rest of the trees.
The Motley Fool January 18, 2012 Sean Williams	This Company is Quickly Approaching the Patent Cliff Earnings exceed expectations at drug manufacturer Forest Laboratories, but worries about future sales mount.
The Motley Fool January 16, 2008 Brian Orelli	Forest Labs Not Down -- Yet Double-digit revenue growth is the highlight of a good quarter for Forest Labs, but the company will need a lot more than one solid quarter to get its stock growing again.
The Motley Fool April 16, 2008 Brian Orelli	Forest Labs' Race Against the Clock Investors don't seem to like Forest Labs' ambitious plans for research and development.
The Motley Fool April 24, 2007 Ryan Fuhrmann	Mixed Foliage at Forest Labs Here's what to look for as Forest Labs prepares for a big loss. Investors, take note.
The Motley Fool September 1, 2004 W.D. Crotty	A Pall Falls Over Forest One of Forest Labs' Alzheimer's drugs fails in phase 3 trials. For investors willing to take the political risk, today's drug news has taken a battered stock, with a great balance sheet, to very reasonable price levels.
The Motley Fool July 14, 2006 Stephen D. Simpson	The Diverging Fortunes of Forest and Teva If a patent ruling holds up, Forest's prospects are much stronger. Unfortunately, the easy money has long since been made in Forest and today's announcement will almost certainly mean another big jump in the stock price.
The Motley Fool July 18, 2006 Stephen D. Simpson	Survival of the Forest New products and a favorable patent ruling give Forest Labs a boost. Investors, this stock remains one to watch.
The Motley Fool October 22, 2009 Robert Steyer	Nibbles Here and There at Forest Labs Forest Laboratories banks on its usual strategy of licensing and collaboration to offset generic-drug threats.
The Motley Fool January 10, 2007 Rich Duprey	Foolish Forecast: Greener Forest Labs The pharmaceutical firm stands tall against competition. When the company releases its third-quarter 2007 financials, investors shouldn't have to reach for their medicine chest.
The Motley Fool May 1, 2006 Stephen D. Simpson	Short-Term Fears Chip Into Forest Investors may be getting a second chance at unconventional Forest Labs. With the stock having pulled back, it's now very close to a tantalizing price.
The Motley Fool January 17, 2006 Stephen D. Simpson	Forest Labs: Is Different Better? Forest isn't your typical pharmaceutical company, and that's both its boon and its bane for investors.
The Motley Fool October 30, 2007 Billy Fisher	Is Forest Labs' Nebivolol Ready for Prime Time? Shareholders of the pharmaceutical company have been looking for a way to boost their floundering stock. The FDA's likely approval of hypertension drug Nebivolol may be the answer.
The Motley Fool January 19, 2007 Billy Fisher	The Best Drug Stock for 2007: Forest Laboratories Management shows confidence in its company, which has been busy with expansion. Investors, take note.
The Motley Fool January 27, 2009 Robert Steyer	Another Angle for Fibromyalgia In the past 18 months, the FDA has approved three drugs that can be used to treat the disease. Which pharma companies will benefit?
The Motley Fool February 22, 2011 Ryan McBride	Forest Labs Snaps Up Clinical Data This deal is the latest proof that drug developers with FDA-approved treatments remain hot buyout targets in a pharma industry that is starved for new products to replace brand-name drugs.
The Motley Fool January 25, 2011 Brian Orelli	FDA Approved -- Now Will It Sell? There's still plenty of uncertainty in Clinical Data's shares.
The Motley Fool February 22, 2011 Brian Orelli	Timber! Clinical Data Falls. Forest Labs cuts down Clinical Data. Clinical Data announced today that it agreed to be purchased by Forest Labs for $30 per share.
The Motley Fool September 11, 2007 Brian Orelli	Teva Spending Plenty of Time in Court Three patent disputes in one week keeps the lawyers busy: Teva and Novartis have been locked in dispute over Novartis' Famvir tablets... Teva and Forest spar over patents for Lexapro... Teva and Wyeth argue over Protonix...
The Motley Fool March 31, 2005 Stephen D. Simpson	Another "No" for Lexapro This latest FDA setback shouldn't hurt Forest Labs much, and the shares look like a bargain.
The Motley Fool October 16, 2007 Billy Fisher	Forest Labs Isn't Out of the Woods Yet The drugmaker's Q2 profit falls, but the company raises its full-year forecast.
The Motley Fool October 5, 2004 W.D. Crotty	Lots of Profits in This Forest Drug manufacturer Forest Laboratories, down sharply from its high, offers value and growth.
The Motley Fool September 30, 2010 Brian Orelli	Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers.
The Motley Fool April 12, 2004 Brian Gorman	Forest Labs Faces Skeptics Its star drug Namenda, a new treatment for Alzheimer's disease, is taking heat from doctors.
The Motley Fool January 29, 2010 Brian Orelli	How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years.
The Motley Fool February 9, 2006 Stephen D. Simpson	Mylan: Generic Drugs, Premium Price Mylan Labs is a fine company with a rich pipeline -- and an expensive stock.
The Motley Fool April 19, 2005 Stephen D. Simpson	Does Forest Have the Blues? Hugely dependent on a single drug, Forest is in a precarious position. Though the next couple of years could be a little hairier than what most pharma investors are normally accustomed to, Forest is worth a look.
The Motley Fool April 13, 2010 Brian Orelli	Teva Gets Less Generic The generic-drug maker makes a major push into branded-drug development.
The Motley Fool October 18, 2006 Rich Duprey	FDA Expands Alzheimer's Treatment Japan's fourth-largest pharmaceutical Eisai's Aricept wins the right to treat all stages of Alzheimer's. Investors, take note.
The Motley Fool September 30, 2005 Stephen D. Simpson	Two Pharma Trees Fall The news of a phase 3 trial failure hammers both Forest Labs and Cypress Bioscience. Investors, take note.
The Motley Fool July 19, 2005 Stephen D. Simpson	A Clearing in the Forest? Despite so-so results, the biotech stock's slide may finally be over.
The Motley Fool October 18, 2005 Stephen D. Simpson	Forest Labs' Clear-Cut Woes Patent litigation, generic competition, and drug development troubles nibble away at this pharmaceutical. Investors, take note.
The Motley Fool January 12, 2006 Stephen D. Simpson	Forest Keeps Reloading An agreement with Mylan Labs gives Forest access to a drug that could be launched in 2006. Investors, take note.
The Motley Fool November 29, 2005 Stephen D. Simpson	Forest Seeds Future Growth A new deal with long-term benefits signals that the pharmaceutical remains credible. Patient investors may yet find this stock worth some due diligence.
The Motley Fool January 21, 2004 Alyce Lomax	Forest Labs' High Hopes Alzheimer's treatment drug Namenda seems to be Forest's strong suit.
The Motley Fool October 8, 2007 Brian Orelli	New FDA Regulations for Drugmakers To deal with a growing backlog of pending applications, the FDA plans to stop its first-come, first-served system.
The Motley Fool December 3, 2007 Brian Orelli	Nebivolol's Almost Approvable Letter Forest and Mylan get an approvable letter for Nebivolol.
The Motley Fool May 28, 2010 Brian Orelli	Innovators Will Rule the Economic Crisis Roche's CEO says two areas of health care can prosper. I agree.
The Motley Fool February 15, 2006 Rich Duprey	Eisai Eyes Alzheimer's Market Japan's Eisai Pharmaceuticals launches another challenge to Forest Labs' Alzheimer's drug. Investors, take note.
The Motley Fool June 29, 2007 Rich Duprey	No More Mr. NICE Guy Pharmaceuticals take British advisory agency to court to approve Alzheimer's treatment.
The Motley Fool June 29, 2009 Brian Orelli	Your Company Has Been Raided. What Now? Lately, investors have had to worry about pharmaceutical companies keeping their drugs on the market.
The Motley Fool June 13, 2007 Billy Fisher	The Best Drug Stock for 2007 Revisited With half of the season left, anything can happen and no lead is safe -- especially in the biotech/pharmaceutical industry. For now the leader, Endo Pharmaceutical, is head and shoulders above the rest.
Scientific American August 2005 Cathryn M. Delude	Widening the Window Strategies to buy time in treating ischemic stroke: Recently scientists have discovered ways that could extend tissue plasminogen activator's (tPA) window of time, at least for some patients, and have found alternatives that may be both effective and safe beyond three hours.
The Motley Fool September 19, 2011 Sean Williams	Shorts Are Piling Into These Stocks. Should You Be Worried? Are the shorts blowing smoke, or is there substance to their worries?
The Motley Fool August 29, 2008 Brian Orelli	A Lawsuit Loss to Remember Barr Pharmaceuticals and Mylan get the patent overturned on Johnson & Johnson's Alzheimer's drug.
The Motley Fool August 1, 2005 Stephen D. Simpson	Teva: Built to Last? Israeli generics giant Teva Pharmaceuticals is a high-quality company trading at a level that should still provide patient investors with solid long-term performance.
The Motley Fool November 19, 2008 Brian Orelli	Depressing News for Drugmakers Antidepressants aren't that different from each other, says a recent report.
The Motley Fool December 19, 2007 Brian Orelli	New Beta Blocker on the Crowded Street Forest and Mylan receive FDA approval for Bystolic. Investors, take note.
The Motley Fool January 27, 2011 Rich Smith	What's Behind the Run-Up at Rexahn? The pharmaceutical's hot streak could soon burn up all its cash.
The Motley Fool May 12, 2004 Phil Wohl	Mylan's Big Break? The maker of generic pimple cream wants to lead the pack. Can it?